Biopharmaceutical company Aptorum Group announced that a patent from the U.S. Patent and Trademark Office has been issued for the company's rapid pathogen infectious disease liquid biopsy diagnostics (RPIDD) technology.
The patent covers DNA library preparation for the RPIDD technology from samples that include more than one type of nucleic acid, the company said. The technology was developed by A*Star, a Singapore-based firm with which Aptorum has an exclusive licensing agreement.
